Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
Muhammad Ajmal, Jacob Friedman, Qurat Ul Ain Riaz Sipra, Tom Lassar
Abstract
Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.
Topics & Concepts
MedicineRivaroxabanAtrial fibrillationStroke (engine)Venous thrombosisPulmonary embolismCoronary artery diseaseThrombosisApixabanIntensive care medicineHeart failureDiseaseCardiologyInternal medicineWarfarinMechanical engineeringEngineeringAtrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAntiplatelet Therapy and Cardiovascular Diseases